Project Details
Description
Phase 1/2, dose-escalation study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of SPK-3006 in adults with late-onset Pompe disease
| Status | Finished |
|---|---|
| Effective start/end date | 6/1/20 → 10/1/21 |
Funding
- SPARK THERAPEUTICS, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.